NeuroKaire

Executive Summary

NeuroKaire (formerly GenetikaPlus) is a Boston-based diagnostics company pioneering personalized treatment approaches for psychiatric and neurological conditions. By leveraging advanced biomarker and genomic analysis, the company aims to transform how these complex diseases are treated and how new drugs are discovered. Founded in 2021, NeuroKaire operates at the intersection of precision medicine and neuroscience, addressing the significant unmet need for tailored therapies in mental health and neurology. Although still in early stages with limited public data, the company's focus on a high-impact area positions it for potential growth as it seeks to validate and commercialize its diagnostic platform.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for lead diagnostic test45% success
• Q2 2026Publication of pivotal clinical validation study in peer-reviewed journal60% success
• Q3 2026Strategic partnership with major pharmaceutical company for drug development35% success